MX2021007063A - Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral. - Google Patents

Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral.

Info

Publication number
MX2021007063A
MX2021007063A MX2021007063A MX2021007063A MX2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A
Authority
MX
Mexico
Prior art keywords
deutetrabenazine
dyskinesia
cerebral palsy
treatment
directed
Prior art date
Application number
MX2021007063A
Other languages
English (en)
Inventor
Frank Schneider
Mark Forrest Gordon
Juha- Matti SAVOLA
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2021007063A publication Critical patent/MX2021007063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación se refiere a métodos para tratar la discinesia en la parálisis cerebral en pacientes humanos usando deutetrabenazina y sus metabolitos activos.
MX2021007063A 2018-12-13 2019-12-13 Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral. MX2021007063A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US201962801450P 2019-02-05 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
MX2021007063A true MX2021007063A (es) 2021-12-10

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007063A MX2021007063A (es) 2018-12-13 2019-12-13 Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral.

Country Status (15)

Country Link
US (3) US11324732B2 (es)
EP (1) EP3893876A1 (es)
JP (1) JP2022519007A (es)
KR (1) KR20210114946A (es)
CN (1) CN113395966A (es)
AU (1) AU2019395250A1 (es)
BR (1) BR112021011386A2 (es)
CA (1) CA3123393A1 (es)
CL (1) CL2021001554A1 (es)
IL (1) IL283920A (es)
MX (1) MX2021007063A (es)
SG (1) SG11202106344SA (es)
TW (1) TWI784220B (es)
WO (1) WO2020123900A1 (es)
ZA (1) ZA202104786B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2978006C (en) 2015-03-06 2024-06-25 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
JP2020510073A (ja) * 2017-03-15 2020-04-02 オースペックス ファーマシューティカルズ インコーポレイテッド デューテトラベナジンの類似体、その調製及び使用
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진

Also Published As

Publication number Publication date
US20200188371A1 (en) 2020-06-18
TWI784220B (zh) 2022-11-21
CL2021001554A1 (es) 2022-02-11
TW202034917A (zh) 2020-10-01
CN113395966A (zh) 2021-09-14
US20240082225A1 (en) 2024-03-14
KR20210114946A (ko) 2021-09-24
IL283920A (en) 2021-07-29
JP2022519007A (ja) 2022-03-18
CA3123393A1 (en) 2020-06-18
ZA202104786B (en) 2023-12-20
EP3893876A1 (en) 2021-10-20
US20220409597A1 (en) 2022-12-29
AU2019395250A1 (en) 2021-07-29
US11324732B2 (en) 2022-05-10
SG11202106344SA (en) 2021-07-29
BR112021011386A2 (pt) 2021-08-31
WO2020123900A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
PH12018501330A1 (en) Methods and systems for providing stimuli to the brain
EP3920923A4 (en) THERAPEUTICS AND TREATMENT METHODS
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
ZA202104786B (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2020001727A (es) Terapia de combinacion.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2023007680A (es) Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
EP3773266A4 (en) IMPROVED TISSUE TREATMENT DEVICES AND METHODS OF USE THEREOF
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
CR20220072A (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
WO2018229551A3 (en) METHODS OF TREATING A DISORDER RELATED TO THE USE OF OPIOIDS
MX2019015448A (es) Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.
AR122244A1 (es) Métodos para el tratamiento de la discinesia en la parálisis cerebral
EA202191665A1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
EP3713589A4 (en) APRATYRAMIDE-BASED THERAPEUTIC AGENTS AND TREATMENT METHODS
AU201813182S (en) Plantar Fasciitus Strengthening Pad
MX2021016052A (es) Formulación transdérmica para el tratamiento del dolor y/o la inflamación.
NZ761505A (en) Mpo inhibitors for use in medicine